Glaucoma and OHT micro-implants

THE DISEASE

Glaucoma is an ophthalmic disease caused by an increase in intraocular pressure. It is a lifelong disease without a cure. Starting with ocular hypertension (OHT), glaucoma mainly affects people over the age of 45.

The prevalence of glaucoma is increasing worldwide, partly because of the ageing of the population. It is estimated that nearly 80 million people in the world today have glaucoma, almost half of whom are unaware of it. This figure is expected to rise to 111.8 million by 2040.

THE SYMPTOMS

The symptoms are very discreet, as the visual field gradually diminishes, and the patient naturally adapts to it. While regular screening and treatment can slow the development of the disease, the resulting visual loss is unfortunately irreversible.

 

THE CURRENT TREATMENT

The current first-line treatment of glaucoma and ocular hypertension is based mainly on the administration of eye drops by patients themselves every day for the rest of their life. The major treatment issue is poor patient compliance, due to the difficulty of self-administering eye drops, the random dosing, and the various side effects (fatigue, breathing difficulties, eye irritation, etc.).

Around 50% of patients today are not receiving the optimum treatment.

THE UNMET NEED

The unmet medical need expressed by ophthalmology specialists is the need for a treatment that would:

  1. improve patient compliance: easier dosage and administration, particularly for the elderly;
  2. limit or even eliminate the side effects associated with systemic administration;
  3. have for the longest duration of action possible.

OUR SOLUTIONS

TimoD

TimoD is a intraocular micro-implant ensuring the sustained release of timolol for the local treatment of glaucoma and ocular hypertension (OHT) for up to 9 years.

  • Discovery

  • Pre-Clinical

  • Clinical
    Phase I

  • Clinical
    Phase II

  • Clinical
    Phase III

  • Regular
    Approval

Clinical Phase I

TimoD

Technology

TimoD is our non-biodegradable intraocular microscopic implant (300-µm-thick) to be placed in the sulcus of the eye, behind the iris, exactly on the site of action (namely where ciliary bodies produce aqueous humor).

It delivers the optimal quantity of the active ingredient, timolol, to treat glaucoma in a sustained, controlled manner, for up to 9 years.

This location enables extremely precise and targeted action, maximizing the effectiveness of the treatment, and poses no risk to the endothelial cells of the cornea.

Implantation

The TimoD implant is positioned quickly and safely with a dedicated injector, during a routine and minimally invasive ophthalmic surgery, lasting less than 15 minutes.

That is exactly the same as a cataract surgery (same incision, same gestures) allowing concomitant surgery of both cataract and glaucoma in one simple procedure.

What makes it different ?

  • Circular non-biodegradable micro-implant
  • Flexible ring with an eyelet used for easy exchange of the implant
  • Local delivery
  • Up to 9 years intraocular release
  • Reduction of side effects
  • Therapeutic dose / 1000 (compared to eye drops)
  • Zero-order sustained release
  • 100 % patient compliance